CSL is an Australian biotech company with a market cap of more than A$130 billion dollars, making it the country’s third biggest listed company, behind BHP and Commonwealth Bank.
In this week’s podcast, Rebecca Jones asks Bloomberg News reporter Amy Bainbridge and senior editor Jason Gale how CSL became a market favorite and about the headwinds it’s facing in the post-pandemic era.
See omnystudio.com/listener for privacy information.
